Financing ·
Secures $80M tranche of up to $150M senior term loan facility with K2 HealthVentures
XFORX4 Pharmaceuticals, Inc
X4 Pharmaceuticals entered into a Loan and Security Agreement with K2 HealthVentures for a senior secured term loan facility totaling up to $150 million. The first tranche, amounting to $80 million, was funded on October 7, 2026, and used to repay the outstanding obligations under the prior Hercules Loan Agreement, which had approximately $75 million in principal plus fees. An additional $70 million remains available at the company's request, subject to lender approval. The facility carries a variable interest rate with an initial interest-only period through October 1, 2029, and matures on October 1, 2030. It includes a conversion option allowing lenders to convert up to $15 million of principal into common stock at $3.2341 per share. X4 Pharmaceuticals is a biotechnology company developing therapies for rare hematology diseases.